STAT3 and neoplasm: Third,we characterized the selective killing profile of this small-moleculeSTAT3 inhibitor by testing the anticancer activities of STAT3-negativePC3 cells and a variety of STAT3-dependent tumor cells, includingPDAC cells, and liver cancer cells.